ADMS News and Press, Adamas Pharmaceuticals Inc. From 02/23/21

Adamas Pharmaceuticals, Inc. (ADMS) Q4 2020 Earnings Conference Call February 23, 2021 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Representative Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss ȁ...

Adamas Pharma (ADMS): Q4 GAAP EPS of -$0.64 misses by $0.14.Revenue of $21M (+28.4% Y/Y) beats by $0.35M.Press Release For further details see: Adamas Pharma EPS misses by $0.14, beats on revenue

Fourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019 Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019 Second indication received February 2021 for GOCOVRI as an adjunctive treatment to levodopa/carbidopa i...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m...

Adamas Pharma shares surged ([[ADMS]] +32.3%) after its GOCOVRI treatment won expanded approval from the U.S. FDA to be used as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes ((the reemergence of stiffness, rigidity and...

- GOCOVRI is now the first and only medication approved to treat OFF and dyskinesia motor complications - - Adamas to host webcast conference call today at 4:30 pm ET/1:30 pm PT - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and deli...

After a gain of ~6.4% today, the shares of Adamas Pharmaceuticals (ADMS) was halted for trading with news pending.The news underlying the trading halt has not been specified, however, today is the FDA action date for the company’s marketing application for Gocovri (amantadine) to treat...

Adamas Pharmaceuticals (ADMS) inks settlement agreement with Zydus Pharmaceuticals resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application ((ANDA)) seeking FDA approval to market a generic version of Gocovri (amantadine) extended-release capsules. Under the...

- Adamas grants Zydus license for generic version of GOCOVRI ® as of March 4, 2030 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurol...

Adamas has become much less exciting the last few years with sales of GOCOVRI slowing in its second year. They decided to give up on attempting to treat the walking speed in those with Multiple Sclerosis with GOCOVRI after lackluster results. Hope remains with a new CEO, Neil McFa...